Get started
Author

Heidi J. Einolf

Observed names: Einolf J. Heidi, Einolf, Heidi, Einolf, Heidi J., H J Einolf, H. Einolf, H. J. Einolf, Heidi Einolf, Heidi J Einolf
Observed institutions: AstraZeneca (United Kingdom), University of Maryland, Baltimore, Novartis (Switzerland), Merck & Co., Inc., Rahway, NJ, USA (United States), Biogen (United States), National Institutes of Health, Amgen (United States), State University of New York, Pharmaceutical Research and Manufacturers of America, Corning (United States), University of Wisconsin–Madison, Alnylam Pharmaceuticals (United States), University of Massachusetts Chan Medical School, Eli Lilly (United States), University of New Mexico, Pfizer (United States), Genentech, GlaxoSmithKline (United Kingdom), Vanderbilt University, Purdue University West Lafayette, AbbVie (United States), Sanofi (France), Novartis (India), Bristol-Myers Squibb (United States), EMD Serono, Inc. (United States), Insmed (United States), GlaxoSmithKline (United States), Novartis (United States), Sekisui XenoTech (United States), AstraZeneca (Sweden), AstraZeneca (United States), Eisai (United States), Boehringer Ingelheim (United States), UMass Memorial Medical Center, Daiichi Sankyo (United States), Astellas Pharma (United States), Celgene (United States), Novartis Institutes for BioMedical Research, Novartis Institute For Tropical Diseases, Merck Healthcare KGaA, Darmstadt (Germany), GlaxoSmithKline Research & Development Limited (United Kingdom), Takeda Oncology (United States), Janssen Research & Development (United States), Stony Brook University, Vertex Pharmaceuticals (United States), Bayer (Germany), Vanderbilt University Medical Center, Incyte (United States)
ORCID: 0009-0001-4966-7645
Observed ORCID: 0009-0001-4966-7645
OpenAlex ID: A5010226778
THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE
2003 · Thorir D. Bjornsson, John T. Callaghan, et al. · Drug Metabolism and Disposition · 793
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective
2018 · Mohamad Shebley, Punam Sandhu, et al. · Clinical Pharmacology & Therapeutics · 413
PDF
The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America
2009 · Scott W. Grimm, Heidi J. Einolf, et al. · Drug Metabolism and Disposition · 317
The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective
2003 · Thorir D. Bjornsson, John T. Callaghan, et al. · The Journal of Clinical Pharmacology · 315
In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective
2009 · Valeria Chu, Heidi J. Einolf, et al. · Drug Metabolism and Disposition · 167
Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
2008 · Handan He, Phi Tran, et al. · Drug Metabolism and Disposition · 141
Fidelity of Nucleotide Insertion at 8-Oxo-7,8-dihydroguanine by Mammalian DNA Polymerase δ
2001 · Heidi J. Einolf, F. Peter Guengerich · Journal of Biological Chemistry · 132
PDF
Comparison of different approaches to predict metabolic drug-drug interactions
2007 · H. J. Einolf · Xenobiotica · 131
Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective
2016 · Tonika Bohnert, Aarti Patel, et al. · Drug Metabolism and Disposition · 111
Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug
2013 · Md L T Vieira, B Kirby, et al. · Clinical Pharmacology & Therapeutics · 105
Steady-State and Pre-Steady-State Kinetic Analysis of 8-Oxo-7,8-dihydroguanosine Triphosphate Incorporation and Extension by Replicative and Repair DNA Polymerases
1998 · Heidi J. Einolf, Nathalie Schnetz-Boutaud, et al. · Biochemistry · 97
Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data
2013 · H J Einolf, L Chen, et al. · Clinical Pharmacology & Therapeutics · 96
Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance
2018 · Jane R. Kenny, Diane Ramsden, et al. · Drug Metabolism and Disposition · 70
PDF
Cytochrome P450 1A2 Detoxicates Aristolochic Acid in the Mouse
2010 · Thomas A. Rosenquist, Heidi J. Einolf, et al. · Drug Metabolism and Disposition · 60
PDF
Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development
2011 · David O. Nettleton, Heidi J. Einolf · Current Topics in Medicinal Chemistry · 59
Kinetic Analysis of Nucleotide Incorporation by Mammalian DNA Polymerase δ
2000 · Heidi J. Einolf, F.Peter Guengerich · Journal of Biological Chemistry · 56
Clinical disposition, metabolism andin vitrodrug–drug interaction properties of omadacycline
2016 · Jimmy Flarakos, Yancy Du, et al. · Xenobiotica · 54
Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model
2019 · Yuan Chen, Tamara D. Cabalu, et al. · CPT Pharmacometrics & Systems Pharmacology · 51
PDF
Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control
2017 · Niresh Hariparsad, Diane Ramsden, et al. · Drug Metabolism and Disposition · 46
Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry Perspective
2016 · Odette A Fahmi, Mohamad Shebley, et al. · Drug Metabolism and Disposition · 46
Efflux Transporters and their Clinical Relevance
2005 · V. Fischer, H. Einolf, et al. · Mini-Reviews in Medicinal Chemistry · 41
Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults
2017 · Sara Armani, Lillian Ting, et al. · Clinical Drug Investigation · 37
PDF
Disposition and metabolism of [14C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects
2016 · Jimmy Flarakos, Yancy Du, et al. · Xenobiotica · 37
Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin
2017 · Helen Gu, Catherine Dutreix, et al. · Drug Metabolism and Disposition · 36
PDF
Role of Cytochrome P450 Enzyme Induction in the Metabolic Activation of Benzo[c]phenanthrene in Human Cell Lines and Mouse Epidermis
1997 · Heidi J. Einolf, William T. Story, et al. · Chemical Research in Toxicology · 36
Works count: 71
Citation count: 3,822
H-index: 30
I10-index: 39
Year
Topic
Type